367 related articles for article (PubMed ID: 32720612)
1. Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study).
Mareev VY; Orlova YA; Pavlikova EP; Matskeplishvili ST; Krasnova TN; Malahov PS; Samokhodskaya LM; Mershina EA; Sinitsyn VE; Mareev YV; Kalinkin AL; Begrambekova YL; Kamalov AA
Kardiologiia; 2020 Jul; 60(6):15-29. PubMed ID: 32720612
[TBL] [Abstract][Full Text] [Related]
2. Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19).
Mareev VY; Orlova YA; Plisuk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malahov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov МA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina EM; Sinitsyn VE; Mareev YV; Shatokhina EA; Begrambekova YL; Kamalov AA
Kardiologiia; 2022 Dec; 62(12):11-22. PubMed ID: 36636972
[TBL] [Abstract][Full Text] [Related]
3. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019].
Xu Y; Qian Y; Gu Q; Tang J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 May; 32(5):559-563. PubMed ID: 32576347
[TBL] [Abstract][Full Text] [Related]
9. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels.
Demelo-Rodríguez P; Cervilla-Muñoz E; Ordieres-Ortega L; Parra-Virto A; Toledano-Macías M; Toledo-Samaniego N; García-García A; García-Fernández-Bravo I; Ji Z; de-Miguel-Diez J; Álvarez-Sala-Walther LA; Del-Toro-Cervera J; Galeano-Valle F
Thromb Res; 2020 Aug; 192():23-26. PubMed ID: 32405101
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation.
Trigonis RA; Holt DB; Yuan R; Siddiqui AA; Craft MK; Khan BA; Kapoor R; Rahman O
Crit Care Med; 2020 Sep; 48(9):e805-e808. PubMed ID: 32618699
[TBL] [Abstract][Full Text] [Related]
13. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
[TBL] [Abstract][Full Text] [Related]
14. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis.
Yu B; Li X; Chen J; Ouyang M; Zhang H; Zhao X; Tang L; Luo Q; Xu M; Yang L; Huang G; Liu X; Tang J
J Thromb Thrombolysis; 2020 Oct; 50(3):548-557. PubMed ID: 32524516
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of coronavirus disease-2019 in pregnancy.
Pereira A; Cruz-Melguizo S; Adrien M; Fuentes L; Marin E; Perez-Medina T
Acta Obstet Gynecol Scand; 2020 Jul; 99(7):839-847. PubMed ID: 32441332
[TBL] [Abstract][Full Text] [Related]
17. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
18. Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban.
Dumitrascu OM; Volod O; Bose S; Wang Y; Biousse V; Lyden PD
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104982. PubMed ID: 32689586
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Factors Associated with Poor Outcomes in Hospitalized Patients with Novel Coronavirus Infection COVID-19.
Boytsov SA; Pogosova NV; Paleev FN; Ezhov MV; Komarov AL; Pevsner DV; Gruzdev KA; Barinova IV; Suvorov AY; Alekseeva IA; Milko OV
Kardiologiia; 2021 Mar; 61(2):4-14. PubMed ID: 33734042
[TBL] [Abstract][Full Text] [Related]
20. Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report.
Sugiyama Y; Tsuchiya T; Tanaka R; Ouchi A; Motoyama A; Takamoto T; Hara N; Yanagawa Y
J Clin Neurosci; 2020 Sep; 79():30-32. PubMed ID: 33070913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
